HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.

Abstract
Multivalent antibodies, either monospecific or bispecific, may improve the efficacy of current therapeutic interventions involving a single monoclonal antibody (mAb). We have applied the Dock-and-Lock (DNL) method, a new platform technology for the site-specific and covalent assembly of modular components into stably tethered complexes of defined composition, to prepare a hexavalent, anti-CD20 antibody, designated Hex-hA20, which comprises six Fabs with one Fc. We show that Hex-hA20 retains the binding activity of all six Fabs, associates with CD20 in lipid rafts, affects antibody-dependent cell-mediated cytotoxicity, but not complement-dependent cytotoxicity, and inhibits proliferation of Daudi, Raji, and Ramos cells in vitro at subnanomolar concentrations without the need for a cross-linking antibody. In addition, Hex-hA20 induces strong homotypical adhesion and is inefficient in stimulating calcium mobilization. Thus, Hex-hA20 exhibits biological properties attributable to both type I and type II anti-CD20 mAbs, as exemplified by rituximab and tositumomab, respectively. Although Hex-hA20 has a short serum half-life, it shows antitumor efficacy in tumor-bearing mice comparable with veltuzumab at equivalent doses. The versatile DNL method was also applied to generate two other multivalent anti-CD20 antibodies without the Fc region, Tri-hA20 and Tetra-hA20, comprising three and four Fabs of veltuzumab, respectively. Similar to Hex-hA20, these were purified to near homogeneity and shown to have potent antiproliferative activity in vitro, thus indicating the need for clustering three or more CD20 molecules on the cell surface to induce growth inhibition.
AuthorsEdmund A Rossi, David M Goldenberg, Thomas M Cardillo, Rhona Stein, Yang Wang, Chien-Hsing Chang
JournalCancer research (Cancer Res) Vol. 68 Issue 20 Pg. 8384-92 (Oct 15 2008) ISSN: 1538-7445 [Electronic] United States
PMID18922911 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, CD20
  • Caspases
  • Calcium
Topics
  • Animals
  • Antibodies, Monoclonal (metabolism, therapeutic use)
  • Antigens, CD20 (immunology)
  • Apoptosis
  • Calcium (metabolism)
  • Caspases (physiology)
  • Cell Line, Tumor
  • Cell Proliferation
  • Cytotoxicity, Immunologic
  • Female
  • Humans
  • Lymphoma (pathology, therapy)
  • Mice
  • Neoplasm Transplantation
  • Transplantation, Heterologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: